Tom A. Hueting
Papers
1
Total Citations
19
H-Index
1
About
Tom A. Hueting is a leading researcher in urologic oncology, with a primary focus on improving risk stratification for prostate cancer through advanced imaging and predictive modeling. His major contributions center on the external validation and refinement of established nomograms—specifically the Memorial Sloan Kettering Cancer Centre and Briganti models—for predicting pelvic lymph node involvement. Hueting’s pivotal 2021 study demonstrated that incorporating clinical stage assessed by multiparametric magnetic resonance imaging (mpMRI) significantly enhances the accuracy of these tools, directly impacting surgical decision-making and patient outcomes. This work, cited 19 times, exemplifies his commitment to translating imaging innovations into clinical practice. Beyond this, Hueting’s research portfolio addresses the integration of mpMRI into prostate cancer staging, bridging the gap between radiological findings and prognostic algorithms. His efforts have helped standardize noninvasive lymph node assessment, reducing unnecessary pelvic lymph node dissections. For students and clinicians, Hueting’s work underscores the critical role of imaging-driven nomograms in precision oncology, offering a model for how rigorous validation studies can refine existing guidelines and improve personalized care in urologic cancers.
Research Focus
Key Achievements
Top Papers
- 1